Vaziva SAS, a French biotech company, has launched its Initial Public Offering (IPO) on the NYSE Euronext Paris, marking a significant step in its ambitious journey to develop innovative therapies for regenerative medicine.

Vaziva SAS, a French biotech company, has made a significant entrance into the European biotech arena with its recent IPO on the NYSE Euronext Paris, positioning itself for growth and innovation in the sector.